Newsroom

RICHMOND, Va.--(BUSINESS WIRE)--Altria Celebrates America by Investing in Our Growers, Communities, Employees and Iconic Brands...

PALATINE, Ill.--(BUSINESS WIRE)--First Bank & Trust Company of Illinois (“FB&T”) today announced the appointment of Nicholas “Nick” Dizonno as its Chief Executive Officer, effective April 20, 2026. Dizonno is a seasoned community bank leader known for driving disciplined credit performance, building reliable and recurring profitability, and leading organizations through periods of transformational growth. A long‑time Chicagoland banking executive and licensed Illinois attorney, Dizonno...

LEVERKUSEN, Germany & ST. LOUIS--(BUSINESS WIRE)--“We appreciate the Court’s careful consideration of FIFRA’s Uniformity language and how its federal preemption provision applies to state-based label warnings. “We believe the U.S. Government and the Company made persuasive arguments that state-based warning claims ‘in addition to or different from’ warning labels approved by EPA under FIFRA, as in Durnell, are preempted, and this is necessary to avoid a patchwork of 50 different warning labels....

FRANKENMUTH, Mich.--(BUSINESS WIRE)--Frankenmuth Insurance has earned a place among the top 20 auto insurers in the nation in the CRASH Network’s 2026 Insurer Report Card, securing a spot on this year’s Insurer Report Card Honor Roll. Out of 91 insurers evaluated, Frankenmuth Insurance received an overall grade of “B,” reflecting strong performance in claims handling as rated by collision repair professionals across the country. The company’s score remains well above the national average, reinf...

FRAMINGHAM, Mass.--(BUSINESS WIRE)--The Ameresco 2025 Impact Report highlights performance and progress across three impact pillars – People, Planet, and Policy....

NEW YORK--(BUSINESS WIRE)--Saba Capital Management, L.P. (together with certain of its affiliates, “Saba” or “we”), one of the world’s leading closed-end fund activists and investors, today announced a significant expansion of its investment activities into both public and private BDCs and interval funds – products that share the structural DNA of closed-end funds but have historically offered retail investors little to no secondary market liquidity in their private forms. A Natural Extension o...

SUNNYVALE, Calif.--(BUSINESS WIRE)--Jumio, the leading provider of AI-powered identity intelligence, today announced the appointment of Mark Lorion as chief executive officer. Lorion succeeds Bala Kumar, who has served as president and interim CEO since the start of 2026. Kumar will continue his leadership as president and chief product & technology officer. “I am honored to join Jumio at such a pivotal time, when identity is moving from point-in-time checks to continuous identity intellige...

CAMBRIDGE, Inghilterra--(BUSINESS WIRE)--  Mundipharma annuncia i principali risultati positivi dallo studio clinico di fase III ReSPECT volto a valutare▼ REZZAYO® (rezafungin) per la profilassi delle infezioni fungine invasive in pazienti sottoposti a trapianto allogenico di cellule staminali ematopoietiche Mundipharma oggi ha annunciato i principali risultati positivi dallo studio clinico globale di fase III ReSPECT, volto a valutare REZZAYO® (rezafungin acetato) per la profilassi delle infez...

HAYWARD, Calif.--(BUSINESS WIRE)--Kite Hill, a leader in dairy-free foods, today announced the launch of its Kite Hill Protein Cream Cheese Alternative, a first-of-its-kind dairy-free innovation bringing protein to a traditionally low-protein category. Now available at Whole Foods Market nationwide, the product delivers 4g of protein per 2 tbsp serving—double that of traditional dairy cream cheese*—along with 0g sugar and 0g saturated fat. Gram for gram, it also delivers more protein than typic...

英格兰剑桥--(BUSINESS WIRE)--(美国商业资讯)-- Mundipharma今天宣布，旨在评估用于预防接受异基因造血干细胞移植（HSCT）的成年患者侵袭性真菌病的REZZAYO® （雷扎芬净）的全球ReSPECT三期临床试验取得积极的总体结果。 ReSPECT三期试验是最大规模的抗真菌、多中心、随机、双盲研究之一，旨在评估每周服用一次雷扎芬净与SAR相比，在接受异基因HSCT的成人中预防IFD方面的效果和安全性，包括因假丝酵母菌属、曲霉属和肺孢子菌属。接受异基因HSCT的患者面临很长的免疫抑制期，需要定期接受延长抗真菌预防治疗1。在此方面，差异化给药、改善不良反映状况并降低DDI将大有裨益，并且预期可以实现类似的疗效。 ReSPECT研究已达到美国食品药品监督管理局（FDA）和欧洲药物管理局（EMA）的90天无真菌生存标准的主要终点指标，显示雷扎芬净的效果不弱于SAR（分别为60.7%和59.0%）。这证明雷扎芬净的差异化药代动力学/药效动力学（PK/PD）特征在降低高风险患者发生侵袭性真菌病方面与SAR类似。雷扎芬净具有良好的耐受性，安全特征显示对于免疫受损患者的效益...